




The relative strengths and weaknesses of Relmada Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Relmada Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 172% points. The greatest weakness of Relmada Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 341%, being 112% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	93,984
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,431
Liabilities, Non-Current	0
Other Assets	20
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,061
Other Net Income	1,715
Other Revenues	0
Property and Equipment	0
Research and Development	26,879
Selling, General and Administrative Expense	32,221

Output Variable	Value in 1000 USD
Assets	94,003
Liabilities	7,491
Expenses	59,100
Revenues	0
Stockholders Equity	86,512
Net Income	-57,385
Comprehensive Net Income	-57,385
BaseVar	81,155
ECR before LimitedLiability	259%
Economic Capital Ratio	341%